Boehringer Ingelheim is committed to HIV/AIDS education and is pleased to be a founding sponsor of AEGiS - the most comprehensive Internet resource providing easily accessible and comprehensive up-to-the-minute information on HIV/AIDS.
Boehringer Ingelheim has been committed to the HIV/AIDS community for the past decade. This commitment has resulted in the availability of new therapies for the treatment of HIV/AIDS. VIRAMUNE® (nevirapine), a potent antiretroviral agent belonging to a class of drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs), is a product of original research done at Boehringer Ingelheim Pharmaceuticals. Boehringer Ingelheim recently announced their acquisition of the world-wide marketing rights for the investigational drug tipranavir, the first in a new class of non-peptidic protease inhibitors. This agent is currently being tested in clinical trials. In addition, Boehringer Ingelheim has an active antiviral discovery program working to bring novel agents to the HIV/AIDS community. More than 100 researchers are dedicated to this program, focusing on HIV and hepatitis.
Boehringer Ingelheim Pharmaceuticals, Inc. is a subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT). The Boehringer Ingelheim group of companies, with headquarters in Ingelheim, Germany, has more than 140 affiliated companies and conducts business on every continent. Its product range is focused on ethical human pharmaceuticals -- hospital, prescription and self-medication -- as well as animal health.
For more information, please see www.VIRAMUNE.com and http://us.boehringer-ingelheim.com